Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Nov;206(4):551-61.
doi: 10.1007/s00213-009-1591-7. Epub 2009 Jun 16.

The endocannabinoid system as a target for modelling psychosis

Affiliations
Review

The endocannabinoid system as a target for modelling psychosis

Dagmar Koethe et al. Psychopharmacology (Berl). 2009 Nov.

Abstract

Introduction: Model psychosis is characterised by experimentally induced symptoms of withdrawal from reality, frequently accompanied by perceptual disturbances, thought disorders, delusional ideas and sometimes by hallucinations. These "altered states of consciousness" provide a long-standing and valid approach to enhance our understanding of certain aspects of schizophrenia.

Discussion: Targeting the endocannabinoid system to investigate its involvement in the pathophysiology of schizophrenia became increasingly relevant with the discovery of this system and amounting epidemiological evidence for a deleterious influence of cannabis use on both manifestation and course of the disease. The majority of studies in the field are targeted to investigate drug effect of cannabis and cannabinoids not immediately related to psychosis.

Conclusion: In this review, we summarise studies relevant for or designed as model psychosis experiments. Based on the data available, we examine the contribution of these studies to an improved neurobiological assessment of endocannabinoid functioning in psychosis and schizophrenia. An outline for future studies in the field and cross-links to other approaches to model psychosis is provided.

PubMed Disclaimer

References

    1. Neuropsychopharmacology. 2003 Jul;28(7):1356-65 - PubMed
    1. Pharmacol Biochem Behav. 1998 Feb;59(2):287-93 - PubMed
    1. Schizophr Res. 2007 Aug;94(1-3):29-36 - PubMed
    1. Neuropsychopharmacology. 2004 Feb;29(2):417-26 - PubMed
    1. Acta Psychiatr Scand. 1989 Feb;79(2):118-28 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources